Roche's Tasmar Approvable In USA
Roche has been sent an approvable letter from the US Food and DrugAdministration for Tasmar (tolcapone), its catechol-o-methyltransferase (COMT) inhibitor for the treatment of Parkinson's disease.
Once approved, Tasmar will be sold in the USA by Novartis, and sales of the drug are forecast to reach over $250 million by 2002, according to analysts. It was first approved in Switzerland earlier this year (Marketletter March 31), and has also been given a positive opinion by the European Committee on Proprietary Medicinal Products.
Launch of the product is scheduled later in the year in both Europe and the USA, and it seems likely that it will be the first COMT inhibitor to reach the market. The other contender is Orion's entacapone, which is near the end of Phase III trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze